Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRT501
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SRT501 is a micronized oral formulation of resveratrol, a naturally occurring polyphenol, developed by Sirtris (a GSK Company). The micronization process was designed to enhance the bioavailability and absorption of resveratrol, which typically exhibits poor pharmacokinetic properties in standard formulations. SRT501 acts as an activator of Sirtuin 1 (SIRT1), a NAD+-dependent deacetylase that regulates various metabolic, inflammatory, and cell-survival pathways. The drug was evaluated in Phase 1 and Phase 2 clinical trials for several indications, including colorectal cancer with hepatic metastases, type 2 diabetes, and multiple myeloma. However, GSK discontinued the development of SRT501 in 2010 following safety concerns, specifically the occurrence of acute renal failure in patients during a Phase 2 trial for multiple myeloma.
- Other names
- micronized resveratrol
02
Targets
SIRT1 (NAD-dependent protein deacetylase sirtuin-1)SIRT5 (NAD-dependent protein deacylase sirtuin-5, mitochondrial)SIRT3 (NAD-dependent protein deacetylase sirtuin-3)
Beyond the preview
Go deeper on SRT501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRT501.